Wasatch Advisors Inc. increased its holdings in shares of Flexion Therapeutics Inc (NASDAQ:FLXN) by 27.8% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 828,224 shares of the specialty pharmaceutical company’s stock after buying an additional 180,293 shares during the period. Wasatch Advisors Inc.’s holdings in Flexion Therapeutics were worth $15,496,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of the stock. State Board of Administration of Florida Retirement System boosted its position in Flexion Therapeutics by 22.9% during the 2nd quarter. State Board of Administration of Florida Retirement System now owns 15,896 shares of the specialty pharmaceutical company’s stock worth $411,000 after buying an additional 2,960 shares during the period. Redmile Group LLC boosted its position in Flexion Therapeutics by 33.5% during the 2nd quarter. Redmile Group LLC now owns 13,260 shares of the specialty pharmaceutical company’s stock worth $343,000 after buying an additional 3,330 shares during the period. Alps Advisors Inc. boosted its position in Flexion Therapeutics by 8.5% during the 2nd quarter. Alps Advisors Inc. now owns 54,622 shares of the specialty pharmaceutical company’s stock worth $1,412,000 after buying an additional 4,272 shares during the period. Dupont Capital Management Corp boosted its position in Flexion Therapeutics by 15.9% during the 3rd quarter. Dupont Capital Management Corp now owns 31,688 shares of the specialty pharmaceutical company’s stock worth $593,000 after buying an additional 4,354 shares during the period. Finally, Schwab Charles Investment Management Inc. boosted its position in Flexion Therapeutics by 3.0% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 179,658 shares of the specialty pharmaceutical company’s stock worth $4,645,000 after buying an additional 5,257 shares during the period. Institutional investors and hedge funds own 98.38% of the company’s stock.

Several equities research analysts recently commented on the stock. BidaskClub downgraded shares of Flexion Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, July 27th. Zacks Investment Research downgraded shares of Flexion Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, August 13th. ValuEngine downgraded shares of Flexion Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, September 21st. Finally, Wells Fargo & Co set a $39.00 price target on shares of Flexion Therapeutics and gave the stock a “buy” rating in a research report on Monday, October 22nd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company’s stock. Flexion Therapeutics has an average rating of “Buy” and a consensus price target of $36.20.

Shares of NASDAQ FLXN opened at $16.21 on Thursday. The company has a market capitalization of $614.04 million, a PE ratio of -3.90 and a beta of 1.13. Flexion Therapeutics Inc has a 52-week low of $13.36 and a 52-week high of $29.10. The company has a debt-to-equity ratio of 1.02, a quick ratio of 8.74 and a current ratio of 8.88.

Flexion Therapeutics (NASDAQ:FLXN) last issued its quarterly earnings results on Wednesday, November 7th. The specialty pharmaceutical company reported ($1.15) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.24) by $0.09. The firm had revenue of $6.99 million for the quarter, compared to the consensus estimate of $5.93 million. Flexion Therapeutics had a negative net margin of 1,346.87% and a negative return on equity of 88.21%. On average, equities research analysts expect that Flexion Therapeutics Inc will post -4.64 EPS for the current year.

In related news, insider Michael D. Clayman acquired 5,000 shares of the stock in a transaction dated Friday, November 9th. The stock was bought at an average price of $17.10 per share, for a total transaction of $85,500.00. Following the purchase, the insider now directly owns 83,295 shares of the company’s stock, valued at approximately $1,424,344.50. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO David Arkowitz acquired 4,000 shares of the stock in a transaction dated Friday, November 9th. The stock was bought at an average price of $16.56 per share, with a total value of $66,240.00. Following the purchase, the chief financial officer now directly owns 48,250 shares in the company, valued at $799,020. The disclosure for this purchase can be found here. 14.59% of the stock is currently owned by insiders.

COPYRIGHT VIOLATION NOTICE: “Wasatch Advisors Inc. Acquires 180,293 Shares of Flexion Therapeutics Inc (FLXN)” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this story on another website, it was illegally stolen and reposted in violation of United States and international copyright law. The correct version of this story can be accessed at https://www.thecerbatgem.com/2018/11/15/wasatch-advisors-inc-acquires-180293-shares-of-flexion-therapeutics-inc-flxn.html.

Flexion Therapeutics Profile

Flexion Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It lead product candidate includes Zilretta, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee.

Featured Story: When is a capital gain realized?

Want to see what other hedge funds are holding FLXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Flexion Therapeutics Inc (NASDAQ:FLXN).

Institutional Ownership by Quarter for Flexion Therapeutics (NASDAQ:FLXN)

Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.